NETWORK × Carcinoma, Ovarian Epithelial × Gynecologic × Clear all Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Phase 1/2 Completed
88 enrolled
iPocc
Phase 2/3 Completed
655 enrolled
Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer
Phase 2 Completed
275 enrolled 13 charts
OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors
Phase 1 Completed
40 enrolled
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid Tumors
Phase NA Withdrawn
Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection
Phase 1 Terminated
17 enrolled
Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase 2 Completed
50 enrolled
ISIS 5132 in Treating Patients With Metastatic or Recurrent Ovarian Cancer
Phase 2 Completed
22 enrolled
Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors
Phase 1 Completed
14 enrolled
Lurtotecan Liposome in Treating Patients With Advanced or Recurrent Ovarian Epithelial Cancer
Phase 2 Completed
81 enrolled
Ondansetron With/Out Dexamethasone to Prevent Vomiting in Patients Receiving Radiation to the Upper Abdomen
Phase 3 Completed
211 enrolled
Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Phase 3 Completed
819 enrolled
Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission
Phase 3 Withdrawn
Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer
Phase 3 Completed
571 enrolled 9 charts
Enzastaurin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Phase 2 Completed
28 enrolled 14 charts
Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Phase 2 Completed
81 enrolled 10 charts
Mifepristone in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Phase 2 Completed
24 enrolled 12 charts
Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer
Phase 2 Completed
71 enrolled 8 charts
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase 2 Terminated
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Phase 2 Terminated
23 enrolled 9 charts
S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Phase 2 Completed
129 enrolled 17 charts
S0009
Phase 2 Completed
62 enrolled 9 charts
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
Phase 3 Completed
61 enrolled
S0114 Vaccine Therapy in Treating Patients With Gastric, Prostate, or Ovarian Cancer
Phase 1 Terminated
14 enrolled
S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
Phase 3 Completed
308 enrolled
Cetuximab and Carboplatin in Treating Patients With Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Phase 2 Completed
BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors
Phase 2 Completed
76 enrolled
Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube Cancer
Phase 3 Completed
835 enrolled
Laparoscopic Staging in Patients With Ovarian, Fallopian Tube, or Other Primary Abdominal Cancers
Phase 2 Completed
Combination Chemotherapy in Treating Patients With Previously Untreated Stage III or Stage IV Ovarian or Primary Peritoneal Cancer
Phase 1 Terminated
45 enrolled
Liposomal Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase 1 Completed
Nitrocamptothecin in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer
Phase 2 Withdrawn
Paclitaxel and Celecoxib in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer
Phase 2 Terminated
Incidence of Blood Clots in Patients Undergoing Chemotherapy for Solid Tumors
Completed
64 enrolled
Etoposide in Treating Patients With Advanced Ovarian or Cervical Cancer
Phase 2 Terminated
Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer
Phase 1 Terminated
Gemcitabine and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Responded to Previous Cisplatin or Carboplatin
Phase 2 Withdrawn
Economic Outcomes in Patients With Stage III Ovarian Cancer Receiving Paclitaxel and Cisplatin on Clinical Trial GOG-172
Phase NA Withdrawn
Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer
Phase 3 Completed
324 enrolled
Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer
Phase 3 Completed
384 enrolled
Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer
Phase 1 Completed
48 enrolled
Quality of Life in Survivors of Gynecologic Cancer
Completed
311 enrolled
Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer
Phase 1 Completed
24 enrolled
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer
Phase 1 Completed
Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer
Phase 1 Completed
Gemcitabine Plus Cisplatin in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Is Recurrent or Has Not Responded to Platinum-based Chemotherapy
Phase 2 Completed
Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer
Phase 3 Terminated
Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer
Phase 2 Terminated
Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer
Phase 2 Terminated
Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Cancer
Phase 2 Terminated